David Trexler joined ONO PHARMA USA, INC. As the Chief Commercial Officer (CCO) in September 2021. As a member of the executive leadership team and U.S. Board Member, David is responsible for leading the Commercial organization in planning, directing, and executing all commercial objectives to drive corporate growth.

David brings more than 30 years of pharmaceutical and biotechnology experience. Most recently he served as President and Member of the Board of Directors of MorphoSys U.S. Inc., a business of MorphoSys AG, Planegg/Munich, Germany, where he was responsible for establishing Morphosys’ commercial capabilities in preparation for the commercialization and launch of the company’s first product in the U.S. Prior to joining Morhphosys, David held a variety of progressive leadership roles at EMD Serono, including serving as the Senior Vice President, U.S. Oncology Commercial, where he built the first commercial oncology footprint for the company in the U.S. He also previously held leadership roles at Eisai Inc., Mylan Bertek Pharmaceuticals and Sanofi-Aventis Pharmaceuticals. 

David holds an Executive MBA from Fairleigh Dickinson University in Madison, NJ, and a Bachelor of Science Degree in Biology from Lenoir-Rhyne College in Hickory, NC.